Inactive Instrument

Aequus Pharmaceuticals Inc Share Price Toronto S.E.

Equities

CA0076361033

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 13.8L 10.14L 8.46Cr Sales 2023 3L 2L 1.56Cr Capitalization 33.16L 24.38L 20Cr
Net income 2022 -30L -22.06L -18Cr Net income 2023 -20L -14.7L -12Cr EV / Sales 2022 5.17 x
Net Debt 2022 24.88L 18.29L 15Cr Net Debt 2023 48.49L 35.65L 30Cr EV / Sales 2023 32 x
P/E ratio 2022
-1.45 x
P/E ratio 2023
-1.12 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 85.32%
More Fundamentals * Assessed data
Dynamic Chart
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aequus Says Zimed PF Now Available in Canada MT
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada CI
Aequus Pharmaceuticals Announces Zimed PF Website Launch MT
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada MT
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada CI
Aequus Pharmaceuticals Announcds Financing to Support Launch of Zimed Preservative Free MT
Aequus Pharmaceuticals Inc. Increases Its Debt by $400,000 to Support the Launch of Zimed Pf CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors CI
More news
Managers TitleAgeSince
Founder - 01/13/01
Chief Executive Officer 56 03/13/03
Director of Finance/CFO 55 22/16/22
Members of the board TitleAgeSince
Chief Executive Officer 56 03/13/03
Director/Board Member 51 15/21/15
Director/Board Member 54 18/14/18
More insiders
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.
More about the company
1st Jan change Capi.
+31.37% 59TCr
-2.60% 36TCr
+20.83% 33TCr
+5.69% 29TCr
+14.83% 24TCr
+9.93% 21TCr
-6.95% 20TCr
+10.77% 17TCr
+0.10% 16TCr
Other Pharmaceuticals
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW